Article

Glucose Intolerance in Pregnancy Associated with Postpartum Cardiovascular Risk

Glucose intolerance during pregnancy predicts an increased likelihood of postpartum metabolic syndrome. In turn, cardiovascular risk factors at three months postpartum indicates that risk factors may be longstanding and contribute to long-term risk of cardiovascular disease.

Women who have gestational glucose intolerance (a condition less severe than gestational diabetes) exhibit multiple cardiovascular risk factors as early as three months after birth, according to a new study publsihed in the Journal of Clinical Endocrinology & Metabolism.

Researchers in this study sought to evaluate the relationship between gestational glucose intolerance and postpartum risk of metabolic syndrome (defined as the clustering of several cardiometabolic risk factors including obesity, hypertension and low HDL cholesterol). Metabolic syndrome, like gestational diabetes itself, is associated with increased risk of developing type 2 diabetes and cardiovascular disease.

Researchers followed 487 women who underwent oral glucose tolerance testing during pregnancy. Each subject was classified as either having normal glucose tolerance, gestational glucose intolerance or gestational diabetes. At three months postpartum, researchers evaluated each subject’s cardiometabolic characteristics, such as blood pressure, weight, waist measurement and lipid levels.

Findings support that even mild glucose intolerance during pregnancy predicts an increased likelihood of the metabolic syndrome at three months postpartum. The presence of cardiovascular risk factors as early as three months postpartum indicates that these risk factors may be longstanding and contribute to the long-term risk of cardiovascular disease in this patient population.

“The study findings raise the important possibility that women with gestational glucose intolerance and subsequent postpartum metabolic syndrome represent a patient population at particularly high risk for the future development of metabolic and vascular disease,“ said Ravi Retnakaran, MD, of Mount Sinai Hospital and the University of Toronto and lead author of the study. ”Further research with long-term follow-up is needed to address this possibility.”

“Our data also suggests that glucose tolerance screening in pregnancy, as is currently practiced, may provide previously unrecognized insight into a woman’s postpartum cardiovascular risk-factor profile,” said Retnakaran. “Furthermore, glucose tolerance screening may identify subgroups of young women for whom cardiovascular risk-factor monitoring may be warranted.”

Source: Endocrine Society

Related Videos
Steve Nissen, MD | Credit: Cleveland Clinic
Harpreet Bhatia, MD: Benefits of Universal Screening for Lp(a) Levels
Benjamin Scirica, MD | Credit: Brigham and Women's Hospital
Heather Johnson, MD: How to Combat Misconceptions of Statin Drugs in Your Patients
Nihar Desai, MD | Credit: HCPLive.com
Laurence Sperling, MD | Credit: Emory University
Tom C. Nguyen, MD: Evolving Roles of TAVR, SAVR in Aortic Valve Disease | Image Credit: Baptist Health
© 2024 MJH Life Sciences

All rights reserved.